Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study

BACKGROUND: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed the risk of these events and the overall survival (OS) benefit in breast cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Pineda-Moncusí, Marta, Garcia-Giralt, Natalia, Diez-Perez, Adolfo, Tusquets, Ignasi, Servitja, Sonia, Albanell, Joan, Prieto-Alhambra, Daniel, Nogués, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097872/
https://www.ncbi.nlm.nih.gov/pubmed/32231712
http://dx.doi.org/10.1177/1758835920909660
_version_ 1783511066167214080
author Pineda-Moncusí, Marta
Garcia-Giralt, Natalia
Diez-Perez, Adolfo
Tusquets, Ignasi
Servitja, Sonia
Albanell, Joan
Prieto-Alhambra, Daniel
Nogués, Xavier
author_facet Pineda-Moncusí, Marta
Garcia-Giralt, Natalia
Diez-Perez, Adolfo
Tusquets, Ignasi
Servitja, Sonia
Albanell, Joan
Prieto-Alhambra, Daniel
Nogués, Xavier
author_sort Pineda-Moncusí, Marta
collection PubMed
description BACKGROUND: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed the risk of these events and the overall survival (OS) benefit in breast cancer patients treated with AI, compared with TAM-treated patients, in a large population-based cohort. METHODS: This observational cohort study included women diagnosed with breast cancer and treated with TAM or AI. Data were extracted from primary care records in a population database (SIDIAP, System for the Development of Research in Primary Care). Incidence rates of study outcomes are reported. Survival analyses included Kaplan–Meier estimation and Cox proportional hazards models. Sensitivity analysis was carried out, using Fine and Gray models to account for competing risk of death. Confounding was minimized using propensity score adjustment and inverse probability weighting (IPW) adjustment. RESULTS: Data from 3082 postmenopausal women treated with TAM, and 18,455 treated with AI, were available. Adjusted hazard ratios (HRs) [95% confidence interval (CI)] for AI users, compared with TAM group, were 0.93 (95%CI 0.69–1.26) for thromboembolic events (TEEs); 1.13 (95%CI 0.79–1.63) for cardiovascular events, and 0.76 (95%CI 0.70–0.82) for mortality. Additional analyses using competing risk analysis had similar results, while IPW adjustment showed a potential risk of pulmonary embolism (PE) [2.26 (95%CI 1.02–4.97)] in AI-treated patients. CONCLUSIONS: AI users had >20% lower all-cause mortality compared with TAM users, without increasing risk to experience cardiovascular and TEEs. This would locate AI therapy on the first line in clinical practice. Thus, AI might be the most preferable option in adjuvant hormonal therapy choice.
format Online
Article
Text
id pubmed-7097872
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-70978722020-03-30 Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study Pineda-Moncusí, Marta Garcia-Giralt, Natalia Diez-Perez, Adolfo Tusquets, Ignasi Servitja, Sonia Albanell, Joan Prieto-Alhambra, Daniel Nogués, Xavier Ther Adv Med Oncol Original Research BACKGROUND: Tamoxifen (TAM) and aromatase inhibitor (AI) therapies have been associated with increased risk of thromboembolic and cardiovascular events, respectively, in addition to other side effects. This study analysed the risk of these events and the overall survival (OS) benefit in breast cancer patients treated with AI, compared with TAM-treated patients, in a large population-based cohort. METHODS: This observational cohort study included women diagnosed with breast cancer and treated with TAM or AI. Data were extracted from primary care records in a population database (SIDIAP, System for the Development of Research in Primary Care). Incidence rates of study outcomes are reported. Survival analyses included Kaplan–Meier estimation and Cox proportional hazards models. Sensitivity analysis was carried out, using Fine and Gray models to account for competing risk of death. Confounding was minimized using propensity score adjustment and inverse probability weighting (IPW) adjustment. RESULTS: Data from 3082 postmenopausal women treated with TAM, and 18,455 treated with AI, were available. Adjusted hazard ratios (HRs) [95% confidence interval (CI)] for AI users, compared with TAM group, were 0.93 (95%CI 0.69–1.26) for thromboembolic events (TEEs); 1.13 (95%CI 0.79–1.63) for cardiovascular events, and 0.76 (95%CI 0.70–0.82) for mortality. Additional analyses using competing risk analysis had similar results, while IPW adjustment showed a potential risk of pulmonary embolism (PE) [2.26 (95%CI 1.02–4.97)] in AI-treated patients. CONCLUSIONS: AI users had >20% lower all-cause mortality compared with TAM users, without increasing risk to experience cardiovascular and TEEs. This would locate AI therapy on the first line in clinical practice. Thus, AI might be the most preferable option in adjuvant hormonal therapy choice. SAGE Publications 2020-03-25 /pmc/articles/PMC7097872/ /pubmed/32231712 http://dx.doi.org/10.1177/1758835920909660 Text en © The Author(s), 2020 https://creativecommons.org/licenses/by-nc/4.0/ This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Original Research
Pineda-Moncusí, Marta
Garcia-Giralt, Natalia
Diez-Perez, Adolfo
Tusquets, Ignasi
Servitja, Sonia
Albanell, Joan
Prieto-Alhambra, Daniel
Nogués, Xavier
Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
title Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
title_full Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
title_fullStr Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
title_full_unstemmed Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
title_short Thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
title_sort thromboembolic, cardiovascular and overall mortality risks of aromatase inhibitors, compared with tamoxifen treatment: an outpatient-register-based retrospective cohort study
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7097872/
https://www.ncbi.nlm.nih.gov/pubmed/32231712
http://dx.doi.org/10.1177/1758835920909660
work_keys_str_mv AT pinedamoncusimarta thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT garciagiraltnatalia thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT diezperezadolfo thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT tusquetsignasi thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT servitjasonia thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT albanelljoan thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT prietoalhambradaniel thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy
AT noguesxavier thromboemboliccardiovascularandoverallmortalityrisksofaromataseinhibitorscomparedwithtamoxifentreatmentanoutpatientregisterbasedretrospectivecohortstudy